Review



bivalent bnt162b2  (Pfizer Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pfizer Inc bivalent bnt162b2
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2+%EA%B2%B0%EA%B3%BC%EB%A5%BC+%EB%95%8C+%EB%B3%BC+%EC%A2%85+%ED%95%A9%ED%95%B4+%ED%98%88%EC%95%A1%EA%B2%80%EC%82%AC/pmc13154980-26-8-11
    Average 86 stars, based on 1 article reviews
    bivalent bnt162b2 - by Bioz Stars, 2026-11
    86/100 stars

    Images

    1) Product Images from "NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants"

    Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

    Journal: Human Vaccines & Immunotherapeutics

    doi: 10.1080/21645515.2026.2638022

    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Figure Legend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Techniques Used: Comparison, Infection

    Related Articles

    Vaccines:

    Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants
    Article Snippet: Reflecting the changing variant landscape, in August 2022 the US Food and Drug Administration (FDA) granted emergency use authorizations to bivalent formulations of the Moderna and Pfizer-BioNtech mRNA vaccines that target both the ancestral SARS-CoV-2 strain and the Omicron BA.4/5 lineages. .. In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines. ..



    Similar Products

    bivalent bnt162b2  (Pfizer Inc)
    86
    Pfizer Inc bivalent bnt162b2
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bivalent Bnt162b2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2+%EA%B2%B0%EA%B3%BC%EB%A5%BC+%EB%95%8C+%EB%B3%BC+%EC%A2%85+%ED%95%A9%ED%95%B4+%ED%98%88%EC%95%A1%EA%B2%80%EC%82%AC/pmc13154980-26-8-11
    Average 86 stars, based on 1 article reviews
    bivalent bnt162b2 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent omicron ba.1-containing vaccine  (Pfizer Inc)
    90
    Pfizer Inc bnt162b2 bivalent omicron ba.1-containing vaccine
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Bivalent Omicron Ba.1 Containing Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc10101054__reviewer___comments-78-46-41
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent omicron ba.1-containing vaccine - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.1 bivalent booster  (BioNTech)
    90
    BioNTech bnt162b2 ba.1 bivalent booster
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Ba.1 Bivalent Booster, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc12197680-32-3-20
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.1 bivalent booster - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.4/5 bivalent booster  (BioNTech)
    90
    BioNTech bnt162b2 ba.4/5 bivalent booster
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Ba.4/5 Bivalent Booster, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc12197680-33-6-20
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.4/5 bivalent booster - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent (ba.4/ba.5)  (BioNTech)
    90
    BioNTech bnt162b2 bivalent (ba.4/ba.5)
    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; <t>BNT162b2),</t> first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.
    Bnt162b2 Bivalent (Ba.4/Ba.5), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc12112343-48-11-5
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent (ba.4/ba.5) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent wt/omi ba.1  (BioNTech)
    90
    BioNTech bnt162b2 bivalent wt/omi ba.1
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent Wt/Omi Ba.1, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc12001871-452-7-17
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent wt/omi ba.1 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent wt/omi ba.4/ba.5  (BioNTech)
    90
    BioNTech bnt162b2 bivalent wt/omi ba.4/ba.5
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent Wt/Omi Ba.4/Ba.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc12001871-452-8-17
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent wt/omi ba.4/ba.5 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 bivalent  (BioNTech)
    90
    BioNTech bnt162b2 bivalent
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Bivalent, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pmc11961057-250-22-21
    Average 90 stars, based on 1 article reviews
    bnt162b2 bivalent - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra  (Abbott Laboratories)
    90
    Abbott Laboratories bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bnt162b2 Ba.4/5 Bivalent Booster With Iiv4 Influvac Tetra, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/pm40333241-320-0-8
    Average 90 stars, based on 1 article reviews
    bnt162b2 ba.4/5 bivalent booster with iiv4 influvac tetra - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty  (Pfizer Inc)
    90
    Pfizer Inc bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty
    <xref ref-type= Thomas 2022 " width="250" height="auto" />
    Bivalent Bnt162b2 Ba.1 Or Ba.4/5 Mrna Comirnaty, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bivalent+bnt162b2/bnt162b2/10__1016_slash_s2352___3026_ascii40_25_ascii41_00008___0-57-19-27
    Average 90 stars, based on 1 article reviews
    bivalent bnt162b2 ba.1 or ba.4/5 mrna comirnaty - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Journal: Human Vaccines & Immunotherapeutics

    Article Title: NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

    doi: 10.1080/21645515.2026.2638022

    Figure Lengend Snippet: Longitudinal measurements and kinetics of SARS-CoV-2 anti-spike (S) antibody over a 1-y study period. (a) Level of anti-S antibody between different vaccine groups. Data was analysed using one-way ANOVA with Holm-Sidak’s multiple comparisons test. Bars depict mean and 95% CI. (b) Kinetics of anti-S antibody from D28 post-booster. Data presented are geometric mean concentrations and 95% CI. (c) Summary data. (d) Comparison of anti-S titres at D28, D180 and D360, and D360-to-D28 ratio. One multiple linear regression model was fitted for each time point, adjusting for baseline anti-S titres, age group (<60 y; ≥60 y), the interval between first and second boosters (≤1 y; >1 y), primary vaccination series (mRNA-1273; BNT162b2), first booster (mRNA-1273; BNT162b2), sex and prior SARS-CoV-2 infection. GM: geometric mean; GMR: geometric mean ratio. *** p < .001; **** p < .0001.

    Article Snippet: In Singapore, the bivalent mRNA-1273 (ancestral/BA.1, Moderna) and bivalent BNT162b2 (ancestral/BA.4/5, Pfizer) vaccines were added to the National Vaccination Programme from October 2022 and were recommended in place of the original monovalent vaccines.

    Techniques: Comparison, Infection

    <xref ref-type= Thomas 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Thomas 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Biomarker Discovery, Vaccines, Comparison, Saline, Injection

    <xref ref-type= Zhao 2024 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Zhao 2024

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Hayashi 2023 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Hayashi 2023

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Lau 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Lau 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Leuva 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Leuva 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Thomas 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Thomas 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Biomarker Discovery, Vaccines, Comparison, Saline, Injection

    <xref ref-type= Zhao 2024 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Zhao 2024

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Hayashi 2023 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Hayashi 2023

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Lau 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Lau 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection

    <xref ref-type= Leuva 2022 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Vaccines for preventing infections in adults with solid tumours

    doi: 10.1002/14651858.CD015551.pub2

    Figure Lengend Snippet: Leuva 2022

    Article Snippet: As of 30 August 2023, those were: BNT162b2; BNT162b2 Bivalent WT/OMI BA.1; BNT162b2 Bivalent WT/OMI BA.4/BA.5 (Comirnaty; Biontech Pfizer); mRNA1273; mRNA‐1273.214 Original/Omicron BA.1; mRNA‐1273.222 Original/Omicron BA.4/BA.5 (Spikevax; Moderna); AZD12222 (Vaxzevria; AstraZeneca); Ad26.COV2.S (COVID‐19 Vaccine Janssen); Sputnik V (Gamaleya); Sputnik Light (Gamaleya); BBIBP‐CorV* (Sinopharm; Beijing CNBG); CoronaVac* (Sinovac); BBV152* (Covaxin); Ad5‐nCoV (Convidecia); NVX‐CoV2373 (Nuvaxovid; Novavax); VidPrevtyn Beta (Sanofi/GSK); VLA2001* (Valneva).

    Techniques: Control, Infection, Vaccines, Comparison, Injection